Pharmacovigilance on Biosimilars

This session of the Biosimilars 2017 will look into the future and FDA initiatives that have already been announced to include enhanced tracking and follow-up of post marketing surveillance issues, planned improvements in AERS, and pilots of new post market drug-monitoring strategies and ADR related issues.Biosimilar guidelines for pharmacovigilance practice and pharmacoepidemiology are the points that shall be laid emphasis in this session.

U.S. average annual spending growth from 2002 to 2007 was 16% for biologics, compared with 3.7% for drugs. In same proportion pharmacovigilance for biosimilars has been comparatively more than other pharmaceutical products.

 

  • Problems in biosimilar pharmacovigilance
  • Adverse drug reactions with biologics and biosimilar products
  • Detection and evaluation of drug safety signals

Related Conference of Pharmacovigilance on Biosimilars

February 24-25, 2025

2nd International Conference on Pharmacognosy

Madrid, Spain
February 27-28, 2025

8th International on Pharmacy and Pharmaceutical Conference

Prague, Czech Republic
March 10-11, 2025

35th Annual European Pharma Congress

Rome, Italy
April 14-15, 2025

18th European Biosimilars Congress

Paris, France
April 24-25, 2025

18th World Drug Delivery Summit

London, UK
May 05-06, 2025

19th World Drug Delivery Summit

Vancouver, Canada
June 16-17, 2025

3rd Global Online Summit on Nanoscience and Nanotechnology

Zurich, Switzerland
June 23-24, 2025

38th World Congress on Pharmacology

Aix-en-Provence, France
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland

Pharmacovigilance on Biosimilars Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in